Is it Possible to Predict the Onset of Side Effects in Patients Treated with Subcutaneous Buserelin?
この論文をさがす
抄録
Buserelin acetate, a synthetic analog of gonadotropin-releasing hormone(GnRH), is widely used in the treatment of endometriosis and uterine leiomyoma. This study sought to identify predictors of side effects of buserelin treatment. The medical records of 52 patients who received buserelin treatment were reviewed. The patients were divided into two groups based on the presence or absence of the common side effects of abnormal vaginal bleeding and climacteric symptoms, and compared in terms of age, height, weight, BMI, and basal gonadotropin level. Abnormal vaginal bleeding and climacteric symptoms were reported in 69.2% and 61.5% of the patients, respectively. Among patients who did not report these side effects, mean weight and mean BMI were significantly higher than those of patients who reported the side effects. Mean basal level of serum gonadotropins, the LH:FSH ratio, and patient menstrual history were not related to the incidence of these side effects. Those with higher weight and BMI are less likely to have buserelin effects, and those with lower weight and BMI are more likely to have these side effects. So, lower weight and BMI might be a predictors for two common side effects of monthly buserelin treatment.
収録刊行物
-
- Shimane journal of medical science
-
Shimane journal of medical science 28 (1), 21-26, 2011-12-01
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1050282814185869568
-
- NII論文ID
- 120005586310
-
- NII書誌ID
- AA00841586
-
- ISSN
- 03865959
-
- 本文言語コード
- en
-
- 資料種別
- departmental bulletin paper
-
- データソース種別
-
- IRDB
- CiNii Articles